Skip to mainSkip to footer

Carmignac Portfolio Grandchildren: Letter from the Fund Managers - Q3 2025

Author(s)
Mark DENHAM,Obe EJIKEME
Published on
October 16, 2025
Read time
3 minute(s) read
-0.56%
Performance of the Fund in the Q3 2025 (A EUR Share class).
+7.17%
Performance of its reference indicator1 in Q3 2025.
+10.75%
Annualized performance of the Fund since launch (31/05/2019) vs +13.24% for its reference indicator.

Carmignac Portfolio Grandchildren A EUR Acc delivered a performance of -0.56% in the third quarter of 2025, underperforming its reference indicator, which had a performance of +7.17%.

Market environment during the period

In the third quarter of 2025 global developed stock markets delivered a strong return of 7.2%2 as investor sentiment improved significantly, with returns clearly led by technology names most affected by the AI theme. Markets were also supported by increased expectations of near-term easing of rates, especially by the Fed in the US, underpinning valuations. Of course periodic concerns around valuation, the US administration’s policies, and external shocks meant occasional volatility.

European equities also delivered positive performance, albeit more modest, returns compared with the U.S., as the region continued to grapple with subdued economic growth and political uncertainty. The eventual agreement of a 15% tariff between the EU and US on most goods was received well, as was the news later in the quarter that as long as pharmaceutical companies had committed to build manufacturing in the US, they would be exempt from specific tariffs.

How did we fare in this context?

During the third quarter of 2025, the fund underperformed its reference indicator. The strongest contributions came from the Information Technology and Communication Services sectors, with several holdings delivering substantial gains notably Alphabet (+38%), Oracle (+29%), and ASML (+22%). These sectors continued to benefit from robust demand related to artificial intelligence (AI) infrastructure and digital transformation themes.

The Industrials sector also benefited from AI-driven themes, particularly through increased investment in electrification and grid modernisation. We have recently increased our exposure to this area, with a focus on companies positioned to capitalize on these structural shifts. Cable manufacturer Prysmian was a notable contributor, reflecting robust demand for high-voltage transmission cables as Western economies accelerate efforts to address years of underinvestment in electrical infrastructure. Prysmian’s dominant transmission division expanded year-on-year, supported by a record order backlog exceeding five years of production providing strong revenue visibility and earnings resilience for the medium term.

Conversely, as investor sentiment improved and risk appetite rose, traditionally defensive sectors such as Utilities, Consumer Staples, and Healthcare underperformed. The fund’s significant exposure to Consumer Staples and Healthcare consequently detracted from relative performance, with several key holdings, including Vertex, Intuitive Surgical, and Alcon, declining between 10% and 20% over the quarter.

Within Healthcare, sentiment was further undermined by renewed policy concerns under the Trump administration, particularly regarding potential drug price controls and incentives to repatriate pharmaceutical manufacturing to the U.S. via sector-wide tariffs.

Novo Nordisk was a notable detractor, falling 22% over the quarter amid multiple headwinds. Prescription growth for its obesity treatment Wegovy fell short of expectations as the company lost market share to Eli Lilly, compounded by the temporary proliferation of illegal compounders producing copycat GLP-1 drugs prior to recent regulatory crackdowns. These pressures, along with execution challenges, led to a CEO change and a downward revision of full-year guidance in July, events that triggered a further share price fall. Despite these near-term challenges, we have maintained our position. At approximately 14x 2025 rebased earnings, Novo Nordisk now trades at a discount of around two multiple points to the broader market while remaining part of a two-player global duopoly addressing the structurally expanding markets of diabetes and obesity. While valuation appears attractive, we prefer to see evidence of sustained prescription growth and operational improvement before considering an increase in our position, which we continue to monitor closely on a weekly basis.

Consumer staples names such as Colgate and Procter & Gamble fell 11% and 3% respectively as investors preferred other areas of the market, as well as concern that sales estimates for second half of the year may need reducing on subdued consumer demand. We believe any such reduction is likely modest and more than reflected in stock price falls and so we have reinforced our holdings in these names.

Outlook & positioning

Over recent months, we have grown increasingly cautious on cyclical areas of the market, particularly Financials, Technology, and more recently Industrials. Several of our industrial holdings, including Schneider Electric and Prysmian, have shown rising correlation with the strong momentum in AI-related technology stocks, given their exposure to data centre expansion and electrification themes. Following a period of strong performance, we took some profits in Prysmian and exited our position in U.S. company, Comfort Systems.

Within Technology, we continue to hold high conviction in our core positions Microsoft, Nvidia, and Amazon which we believe remain well placed to benefit from the ongoing AI-driven transformation of global enterprise and consumer ecosystems. Microsoft remains our largest holding, and we were encouraged by its strong fiscal third-quarter results released in August. Overall revenue grew 18% year-on-year, while profits rose more than 20%. Notably, Azure reported accelerating growth of 39%, underscoring the strength of our investment thesis centred on cloud computing and AI integration. Although the share price was broadly flat during the quarter, we view this as a temporary pause within a structurally favourable trajectory, given the company’s exceptional fundamentals.

We exited our position in Oracle after the company reported a strong uplift in bookings for its emerging hyperscaler platform, locking in a 17% gain for the fund during the quarter.

Given our concerns about potential policy headwinds for the Healthcare sector under the Trump administration, particularly regarding drug pricing reform and supply chain reshoring we reduced exposure to the sector. This included the gradual reduction and eventual sale of our positions in Stryker and Intuitive Surgical, both of which had represented meaningful weightings. We redeployed the cash to initiate a new position in Spotify as well as DSV which is one of the top global freights forwarders. DSV further cemented its top-tier status by completing the acquisition of Schenker in the first half of the year, creating the largest global logistics player.

In this environment, we continue to prioritise high-quality, secular growth companies with resilient earnings and strong revenue visibility. We believe these businesses are best equipped to navigate uncertainty while delivering compelling long-term returns.

1Reference indicator: MSCI WORLD (USD, net dividends reinvested). Past performance is no guarantee of future results. They are net of fees (excluding any entry fees applied by the distributor).
2Source: Bloomberg. Data as of 30/09/2025.

Carmignac Portfolio Grandchildren

An intergenerational Fund focused on quality, sustainable companies
Discover the fund page

Carmignac Portfolio Grandchildren A EUR Acc

ISIN: LU1966631001
Recommended minimum investment horizon
5 years
Risk indicator*
4/7
SFDR - Fund Classification**
Article 9

*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. **Sustainable Finance Disclosure Regulation (SFDR) 2019/2088. The SFDR classification of the Funds may change over time.

Main risks of the fund

Equity: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.
Currency: Currency risk is linked to exposure to a currency other than the Fund’s valuation currency, either through direct investment or the use of forward financial instruments.
Discretionary Management: Anticipations of financial market changes made by the Management Company have a direct effect on the Fund's performance, which depends on the stocks selected.
The Fund presents a risk of loss of capital. Please refer to the Fund’s prospectus to view the exhaustive list of risks.

Fees

ISIN: LU1966631001
Entry costs
4.00% of the amount you pay in when entering this investment. This is the most you will be charged. Carmignac Gestion doesn't charge any entry fee. The person selling you the product will inform you of the actual charge.
Exit costs
We do not charge an exit fee for this product.
Management fees and other administrative or operating costs
1.71% of the value of your investment per year. This estimate is based on actual costs over the past year.
Performance fees
20.00% when the share class overperforms the Reference indicator during the performance period. It will be payable also in case the share class has overperformed the reference indicator but had a negative performance. Underperformance is clawed back for 5 years. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.
Transaction Cost
0.30% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the quantity we buy and sell.

Performance

ISIN: LU1966631001
Carmignac Portfolio Grandchildren−5.8+21.9+23.0−24.2+28.4+20.3+15.5
Reference Indicator+3.5+26.6+19.6−12.8+31.1+6.3+15.5
Carmignac Portfolio Grandchildren+12.7%+8.8%+10.8%
Reference Indicator+16.4%+14.4%+13.2%

Source: Carmignac at Sep 30, 2025.
Date of 1st NAV : 31/05/2019.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The Fund presents a risk of loss of capital.
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference Indicator: MSCI World NR index

Share

Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.
The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds’ prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com/en, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

  • In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.com/en-gb, or upon request to the Management Company, or for the French Funds, at the offices of the acilities Agent, Carmignac UK Ltd, 2 Carlton House Terrace, London, SW1Y 5AF. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.

  • In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.com/en-ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

  • In Belgium: This document is intended for professional clients. This content has not been validated by FSMA. The decision to invest in the promoted fund should take into account all its characteristics or objectives as described in its prospectus. This communication is published by Carmignac Gestion S.A., a portfolio management company approved by the Autorité des Marchés Financiers (AMF) in France, and its Luxembourg subsidiary Carmignac Gestion Luxembourg, S.A., an investment fund management company approved by the Commission de Surveillance du Secteur Financier (CSSF). “Carmignac” is a registered trademark. “Investing in your Interest” is a slogan associated with the Carmignac trademark. This document does not constitute advice on any investment or arbitrage of transferable securities or any other asset management or investment product or service. The information and opinions contained in this document do not take into account investors’ specific individual circumstances and must never be interpreted as legal, tax or investment advice. The information contained in this document may be partial and could be changed without notice. This document may not be reproduced in whole or in part without prior authorisation. The risks and fees are described in the KID (Key Information Document). The prospectus, KID, the net asset-values and the latest (semi-) annual management report may be obtained, free of charge, in French or in Dutch, from the management company (tel. +352 46 70 60 1) or by consulting its website or www.fundinfo.com. These materials may also be obtained from Caceis Belgium S.A., the financial service provider in Belgium, at the following address: avenue du port, 86c b320, B-1000 Brussels. The Fund (fonds commun de placement or FCP) is a common fund in contractual form conforming to the UCITS Directive under French law. Access to the Fund may be subject to restrictions regarding certain persons or countries. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA. In case of subscription to a fund subject to Article 19bis of the Belgian Income Tax Code (CIR92), the investor will have to pay, upon redemption of his or her shares, a withholding tax of 30% on the income (in the form of interest, or capital gains or losses) derived from the return on assets invested in debt claims. Distributions are subject to withholding tax of 30% without income distinction. In case of subscription in a French investment fund (fonds commun de placement or FCP), you must declare on tax form, each year, the share of the dividends (and interest, if applicable) received by the Fund. Any complaint may be referred to complaints@carmignac.com or CARMIGNAC GESTION - Compliance and Internal Controls - 24 place Vendôme Paris France or on the website www.ombudsfin.be.

The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights at section 5 entitled "summary of investor rights" on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden. Belgium (French) ; Belgium (Dutch)

For Carmignac Portfolio Long-Short European Equities: Carmignac Gestion Luxembourg SA in its capacity as the Management Company for Carmignac Portfolio, has delegated the investment management of this Sub-Fund to White Creek Capital LLP (Registered in England and Wales with number OCC447169) from 2nd May 2024. White Creek Capital LLP is authorised and regulated by the Financial Conduct Authority with FRN : 998349.

Carmignac Private Evergreen refers to the Private Evergreen sub-fund of the SICAV Carmignac S.A. SICAV – PART II UCI, registered with the Luxembourg RCS under number B285278.